GPEx® Lightning Cell Line Development Technology

Speed and efficiency remain major drivers for developers advancing protein-based biologics to first-in-human studies. For 20 years, Catalent’s GPEx^® technology has been used to generate high expressing, highly stable mammalian cell lines, and has supported the development of 16 commercially approved biologics to date.

GPEx^® Lightning further reduces development timelines and can be tailored to the specific needs of each individual program on its path to clinical trials.

URL: https://biologics.catalent.com/biologics/drug-substance/cell-line-development/#gpex-lightning